ARPA-H launches $160M effort to develop custom gene editing drugs
7 hours ago
- #gene editing
- #clinical trials
- #rare diseases
- ARPA-H announces up to $160 million investment for custom gene editing treatments for rare diseases through the THRIVE program.
- The program will support seven teams targeting different organ systems, with each team required to start clinical trials within three years.
- The article is part of STAT+ subscription content covering biotech sector news and analysis.